Richard D.  Francis net worth and biography

Richard Francis Biography and Net Worth

President, CEO & Director of Teva Pharmaceutical Industries

Prior to joining Teva, Mr. Francis served as an operating Partner at Syncona and the Chief Executive Officer of Syncona’s portfolio companies - Purespring Therapeutics and Forcefield Therapeutics.

From 2014 to 2019, Mr. Francis served as the Chief Executive Officer of Sandoz and a member of the Novartis Executive Team. Prior to that, Mr. Francis held various leadership roles over a 13-year tenure at Biogen, including Senior Vice President of U.S. Commercial and Senior Vice President of Global Commercial Strategy. During his time at Biogen Mr. Francis led the successful launch of Tecfidera® in 2013.

Mr. Francis serves as a member of the board of directors of Mettler-Toledo International Inc. since 2016.

He holds a Bachelor of Arts in Economics from The Manchester Metropolitan University.

What is Richard D. Francis' net worth?

The estimated net worth of Richard D. Francis is at least $1.49 million as of February 15th, 2024. Mr. Francis owns 87,125 shares of Teva Pharmaceutical Industries stock worth more than $1,491,580 as of November 23rd. This net worth evaluation does not reflect any other assets that Mr. Francis may own. Additionally, Mr. Francis receives a salary of $6,710,000.00 as President, CEO & Director at Teva Pharmaceutical Industries. Learn More about Richard D. Francis' net worth.

How old is Richard D. Francis?

Mr. Francis is currently 56 years old. There are 6 older executives and no younger executives at Teva Pharmaceutical Industries. Learn More on Richard D. Francis' age.

What is Richard D. Francis' salary?

As the President, CEO & Director of Teva Pharmaceutical Industries Limited, Mr. Francis earns $6,710,000.00 per year. Learn More on Richard D. Francis' salary.

How do I contact Richard D. Francis?

The corporate mailing address for Mr. Francis and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Richard D. Francis' contact information.

Has Richard D. Francis been buying or selling shares of Teva Pharmaceutical Industries?

Richard D. Francis has not been actively trading shares of Teva Pharmaceutical Industries over the course of the past ninety days. Most recently, Richard D. Francis sold 74,530 shares of the business's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $13.15, for a transaction totalling $980,069.50. Following the completion of the sale, the chief executive officer now directly owns 87,125 shares of the company's stock, valued at $1,145,693.75. Learn More on Richard D. Francis' trading history.

Who are Teva Pharmaceutical Industries' active insiders?

Teva Pharmaceutical Industries' insider roster includes Vikki Conway (Acting Head of Global Human Resources), Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Richard Francis (President, CEO & Director), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Eliyahu Kalif (CFO), Roberto Mignone (Director), Mark Sabag (Insider), Eli Shani (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.

Are insiders buying or selling shares of Teva Pharmaceutical Industries?

During the last twelve months, insiders at the sold shares 11 times. They sold a total of 984,382 shares worth more than $15,236,840.56. The most recent insider tranaction occured on November, 20th when EVP Christine Fox sold 19,388 shares worth more than $327,075.56. Insiders at Teva Pharmaceutical Industries own 0.6% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.

Information on this page was last updated on 11/20/2024.

Richard D. Francis Insider Trading History at Teva Pharmaceutical Industries

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2024Sell74,530$13.15$980,069.5087,125View SEC Filing Icon  
See Full Table

Richard D. Francis Buying and Selling Activity at Teva Pharmaceutical Industries

This chart shows Richard D Francis's buying and selling at Teva Pharmaceutical Industries by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries logo
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Read More

Today's Range

Now: $17.12
Low: $16.87
High: $17.13

50 Day Range

MA: $17.70
Low: $16.44
High: $18.78

2 Week Range

Now: $17.12
Low: $9.35
High: $19.31

Volume

5,040,173 shs

Average Volume

7,721,805 shs

Market Capitalization

$19.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87